Trial results

$XENE — azetukalner

Xenon Pharmaceuticals Inc. (XENE) azetukalner: trial results in major depressive disorder (MDD), 2026.

Research by Catalyst Intel

The catalyst

"Xenon completed enrollment in the Phase 3 X-NOVA2 study in MDD with approximately 360 total patients; the topline data readout is now expected in December 2026."

— Xenon Pharmaceuticals Inc., 8-K filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

XENE-AZETUKALNER-2026

Company

Xenon Pharmaceuticals Inc.

Kind

Trial results

Indication

major depressive disorder (MDD)

Window

2026-12-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.